Ozanimod

Ozanimod
Clinical data
Trade names	Zeposia
Other names	RPC-1063
AHFS/Drugs.com	Monograph
MedlinePlus	a620029
License data	EU EMA: by INN; US DailyMed: Ozanimod;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	L04AE02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	19 hours
Identifiers
	IUPAC name 5-(3-{(1S)-1-[(2-Hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile;
CAS Number	1306760-87-1;
PubChem CID	52938427;
DrugBank	DB12612;
ChemSpider	34979946;
UNII	Z80293URPV;
KEGG	D10968; as HCl: D10967;
ChEMBL	ChEMBL3707247;
CompTox Dashboard (EPA)	DTXSID501026488 ;
ECHA InfoCard	100.247.081
Chemical and physical data
Formula	C23H24N4O3
Molar mass	404.470 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)Oc1ccc(cc1C#N)c2nc(no2)c3cccc4c3CC[C@@H]4NCCO;
	InChI InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1; Key:XRVDGNKRPOAQTN-FQEVSTJZSA-N;

Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis.^[3]^[4]^[6]^[7] It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.^[6]

The most common adverse reactions are upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension.^[3]^[8]

Ozanimod was approved for medical use in the United States in March 2020,^[8]^[9]^[10] in the European Union in May 2020,^[4] and in Australia in July 2020.^[1]^[11]

^ ^a ^b ^c "Zeposia Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). July 27, 2020. Retrieved August 16, 2020.
^ "Summary Basis of Decision (SBD) for Zeposia". Health Canada. October 23, 2014. Retrieved May 29, 2022.
^ ^a ^b ^c "Zeposia- ozanimod hydrochloride capsule Zeposia 7-Day Starter Pack- ozanimod hydrochloride kit Zeposia Starter Kit- ozanimod hydrochloride kit". DailyMed. November 16, 2022. Retrieved December 30, 2022.
^ ^a ^b ^c "Zeposia EPAR". European Medicines Agency. March 26, 2020. Retrieved August 17, 2020.
^ "Zeposia Product information". Union Register of medicinal products. Retrieved March 3, 2023.
^ ^a ^b Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, et al. (June 2016). "Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity". British Journal of Pharmacology. 173 (11): 1778–92. doi:10.1111/bph.13476. PMC 4867749. PMID 26990079.
^ Cite error: The named reference BMS PR 20210527 was invoked but never defined (see the help page).
^ ^a ^b "U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis". Bristol-Myers Squibb Company (Press release). March 26, 2020. Retrieved March 26, 2020.
^ "Drug Trials Snapshots: Zeposia". U.S. Food and Drug Administration (FDA). March 25, 2020. Retrieved April 1, 2020. This article incorporates text from this source, which is in the public domain.
^ "Drug Approval Package: Zeposia". U.S. Food and Drug Administration (FDA). April 23, 2020. Retrieved October 3, 2020.
^ Cite error: The named reference Ozanimod hydrochloride AusPAR was invoked but never defined (see the help page).

[Zeposia_APMDS-1] "Zeposia Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). July 27, 2020. Retrieved August 16, 2020.

[2] "Summary Basis of Decision (SBD) for Zeposia". Health Canada. October 23, 2014. Retrieved May 29, 2022.

[Zeposia_FDA_label-3] "Zeposia- ozanimod hydrochloride capsule Zeposia 7-Day Starter Pack- ozanimod hydrochloride kit Zeposia Starter Kit- ozanimod hydrochloride kit". DailyMed. November 16, 2022. Retrieved December 30, 2022.

[Zeposia_EPAR-4] "Zeposia EPAR". European Medicines Agency. March 26, 2020. Retrieved August 17, 2020.

[5] "Zeposia Product information". Union Register of medicinal products. Retrieved March 3, 2023.

[:2-6] Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, et al. (June 2016). "Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity". British Journal of Pharmacology. 173 (11): 1778–92. doi:10.1111/bph.13476. PMC 4867749. PMID 26990079.

[BMS_PR_20210527-7] Cite error: The named reference BMS PR 20210527 was invoked but never defined (see the help page).

[Zeposia_PR-8] "U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis". Bristol-Myers Squibb Company (Press release). March 26, 2020. Retrieved March 26, 2020.

[FDA_snapshot-9] "Drug Trials Snapshots: Zeposia". U.S. Food and Drug Administration (FDA). March 25, 2020. Retrieved April 1, 2020. This article incorporates text from this source, which is in the public domain.

[FDA_approval_package-10] "Drug Approval Package: Zeposia". U.S. Food and Drug Administration (FDA). April 23, 2020. Retrieved October 3, 2020.

[Ozanimod_hydrochloride_AusPAR-11] Cite error: The named reference Ozanimod hydrochloride AusPAR was invoked but never defined (see the help page).

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]